Complete Obstruction, a Real Risk Factor: A Comprehensive Study on Obstruction in Stage IIA Colon Cancer With Propensity Score Matching Analysis

被引:1
|
作者
Oh, Soo Young [1 ,2 ,4 ]
Kim, Chan Wook [1 ,2 ]
Kim, Seonok [3 ]
Kim, Min Hyun [1 ,2 ]
Kim, Young Il [2 ]
Lee, Jong Lyul [1 ,2 ]
Yoon, Yong Sik [1 ,2 ]
Park, In Ja [1 ,2 ]
Lim, Seok-Byung [1 ,2 ]
Yu, Chang Sik [1 ,2 ]
机构
[1] Univ Ulsan, Dept Surg, Coll Med, Div Colon & Rectal Surg, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[2] Asan Med Ctr, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[3] Asan Med Ctr, Dept Clin Epidemiol & Biostat, Seoul, South Korea
[4] Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Surg, Seoul, South Korea
关键词
Chemotherapy; Colorectal cancer; High risk factor; Prognosis; LONG-TERM SURVIVAL; QUALITY-OF-LIFE; COLORECTAL-CANCER; ADJUVANT CHEMOTHERAPY; PERFORMANCE STATUS; BOWEL OBSTRUCTION; POOLED ANALYSIS; RECTAL-CANCER; FLUOROURACIL; OXALIPLATIN;
D O I
10.1016/j.clcc.2024.04.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Microabstract: This study evaluates the prognostic significance of obstructions in stage IIA colon cancer, distinguishing between partial and complete obstructions. It employs a retrospective review of 1914 patients with propensity score matching to analyze oncologic outcomes. Findings reveal complete obstr uction as a significant r isk factor for poorer outcomes, emphasizing the necessity for further research to refine treatment strategies, particularly regarding the efficacy of adjuvant chemotherapy across obstruction types. Background: This study examined the prognostic impact of obstructions in stage IIA colon cancer. The analysis specifically differentiated partial and complete obstructions, analyzing their distinct influences of both on oncologic outcomes. Materials and Methods: A retrospective review was conducted of stage IIA colon cancer cases with the presence of an obstruction. Patients were stratified by whether it was partial or complete based on the severity of obstruction. Propensity score matching was employed to control for confounders. Results: Among 1914 consecutive patients diagnosed with stage IIA colon cancer, 758 patients (597 patients with partial obstruction, 161 patients with complete obstruction) exhibited obstruction, while 1156 patients had no obstruction. The median follow-up period was 126 months. Complete obstruction was associated with poorer diseasefree survival (Hazard ratio (HR) = 1.785, P < .001) and overall survival (HR = 1.853, P = .001). This trend persisted after propensity score matching, patients with complete obstruction showing a worsened disease-free survival (HR = 1.666, P = .028) and overall survival (HR = 1.732, P = .041). Adjuvant chemotherapy showed improved outcomes overall, but its efficacy varied across obstruction types. Conclusion: Differentiating between complete and partial obstructions in stage IIA colon cancer is an important clinical distinction, as our findings suggest that complete obstruction is a significant risk factor for poorer oncologic outcomes. While adjuvant chemotherapy generally improves prognosis in stage IIA colon cancer, the correlation of obstruction type with its efficacy remains uncertain, necessitating further research to refine treatment strategies.
引用
收藏
页码:135 / 146.e3
页数:15
相关论文
共 50 条
  • [1] Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis
    Chen, Xiao-Jiang
    Chen, Guo-Ming
    Wei, Yi-Cheng
    Yu, Hong
    Wang, Xi-Cheng
    Zhao, Zhou-Kai
    Luo, Tian-Qi
    Nie, Run-Cong
    Zhou, Zhi-Wei
    BMC CANCER, 2021, 21 (01)
  • [2] Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis
    Xiao-Jiang Chen
    Guo-Ming Chen
    Yi-Cheng Wei
    Hong Yu
    Xi-Cheng Wang
    Zhou-Kai Zhao
    Tian-Qi Luo
    Run-Cong Nie
    Zhi-Wei Zhou
    BMC Cancer, 21
  • [3] Complete single stage management of left colon cancer obstruction with a new device
    Kim, J
    Chang, B
    Chung, M
    Son, D
    Shim, M
    GASTROINTESTINAL ENDOSCOPY, 2002, 55 (05) : AB114 - AB114
  • [4] Postoperative adjuvant chemotherapy improves survival in stage II colon cancer? A propensity score matching analysis
    Tsukamoto, Ryoichi
    Sugimoto, Kiichi
    Kawano, Shingo
    Niwa, Koichiro
    Ishiyama, Shun
    Kamiyama, Hirohiko
    Komiyama, Hiromitsu
    Takahashi, Makoto
    Kojima, Yutaka
    Goto, Michitoshi
    Tomiki, Yuichi
    Sakamoto, Kazuhiro
    CANCER RESEARCH, 2017, 77
  • [5] Survival comparison of stage IIA rectal cancer with or without neoadjuvant therapy: a SEER database analysis with propensity score matching
    Yan, Han
    Wang, Peng-Yuan
    Wu, Ying-Chao
    Liu, Yu-Cun
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (05) : 2293 - 2305
  • [6] Complete single-stage management of left colon cancer obstruction with a new device
    J.-H. Kim
    D.-H. Shon
    S.-H. Kang
    B.-I. Jang
    M.-K. Chung
    J.-H. Kim
    M.-C. Shim
    Surgical Endoscopy And Other Interventional Techniques, 2005, 19 : 1671 - 1671
  • [7] Complete single-stage management of left colon cancer obstruction with a new device
    J.-H. Kim
    D.-H. Shon
    S.-H. Kang
    B.-I. Jang
    M.-K. Chung
    J.-H. Kim
    M.-C. Shim
    Surgical Endoscopy And Other Interventional Techniques, 2005, 19 : 1381 - 1387
  • [8] Complete single-stage management of left colon cancer obstruction with a new device
    Kim, JH
    Shon, DH
    Kang, SH
    Jang, BI
    Chung, MK
    Kim, JH
    Shim, MC
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2005, 19 (10): : 1381 - 1387
  • [9] Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis
    Tian, Mengxiang
    Zhou, Zhongyi
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (12) : 4241 - 4253
  • [10] Benign gallbladder disease is a risk factor for colorectal cancer, but cholecystectomy is not: A propensity score matching analysis
    Qin, Qiong
    Li, Wei
    Ren, Ao
    Luo, Rong
    Luo, Shiqiao
    FRONTIERS IN ONCOLOGY, 2022, 12